Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4641952)

Published in J Immunol Res on October 29, 2015


Julie Jacobs1, Evelien Smits2, Filip Lardon3, Patrick Pauwels1, Vanessa Deschoolmeester1

Author Affiliations

1: Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium ; Department of Pathology, Antwerp University Hospital, 2650 Edegem, Belgium.
2: Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium ; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, 2650 Edegem, Belgium.
3: Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium.

Associated clinical trials:

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664

A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01375842

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

A Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors | NCT01714739

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758

A Phase 1/2 Study to Evaluate MEDI4736 | NCT01693562

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01633970

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | NCT01876511

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | NCT01772004

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) | NCT01239134

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma | NCT02253992

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | NCT01471210

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer | NCT01352884

A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | NCT02060188

A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469) | NCT02205333

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | NCT02179918

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | NCT02110082

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors | NCT00607048

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | NCT02054806

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | NCT02239900

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | NCT02221960

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | NCT01460134

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | NCT01943461

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With MEDI4736 and MEDI0680 Monotherapy in Subjects With Select Advanced Malignancies | NCT02118337

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | NCT02335918

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | NCT02013804

Ipilimumab and Lenalidomide in Advanced Cancer | NCT01750983

ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | NCT00836888

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | NCT02318394

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | NCT02261220

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | NCT02460224

AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer | NCT02298946

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | NCT01561911

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | NCT02444793

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | NCT02227667

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors | NCT02225002

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01988896

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02408861

Phase I/II Study of PDR001 in Patients With Advanced Malignancies | NCT02404441

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | NCT02383212

A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT02219724

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | NCT02460198

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | NCT02132754

Phase 1b Study of ARGX-110 in Patients With Advanced Malignancies | NCT01813539

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment | NCT00313794

A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT02410512

A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors | NCT02304393

A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors | NCT02350673

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051) | NCT02332668

ADC-1013 First-in-Human Study | NCT02379741

Safety Study of SEA-CD40 in Cancer Patients | NCT02376699

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors | NCT02407990

Articles cited by this

(truncated to the top 100)

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

The B7 family revisited. Annu Rev Immunol (2005) 13.51

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013) 2.75

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer (1997) 2.23

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther (2015) 2.21

Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96

Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95

Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol (2007) 1.94

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73

Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68

LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol (2011) 1.58

OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57

Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med (2007) 1.51

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol (2010) 1.37

Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology (2012) 1.33

Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33

Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut (2011) 1.33

Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29

Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) (2014) 1.29

A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov (2015) 1.24

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res (2010) 1.22

CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol (1998) 1.18

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology (2013) 1.16

FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res (2013) 1.16

Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol (2010) 1.13

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells. Mucosal Immunol (2013) 1.12

Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther (2000) 1.05

A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res (2013) 1.02

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer (2003) 1.01

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01

Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol (2014) 1.00

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer (2010) 0.99

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res (2012) 0.98

Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene (2005) 0.98

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97

PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer (2014) 0.97

B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol (2012) 0.97

Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene (2012) 0.97

Accumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PLoS One (2012) 0.96

Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer (2012) 0.96

CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci (2013) 0.94

Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92

An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Oncoimmunology (2015) 0.92

Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation. Yonago Acta Med (2012) 0.91

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg (2002) 0.91

Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep (2014) 0.90

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med (2004) 0.90

Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther (2015) 0.89

Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells. EMBO J (2015) 0.89

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology (2014) 0.89

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88

Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy (2012) 0.88

Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer (2007) 0.88

Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87

Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. Front Oncol (2013) 0.87

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87

The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol (2014) 0.85

Macrophages: Good guys in colorectal cancer. Oncoimmunology (2013) 0.85

Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology (2013) 0.84

Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese. J Cancer Res Clin Oncol (2015) 0.83

Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol (2011) 0.82

CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep (2004) 0.82

Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol (2007) 0.81

The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs (2014) 0.81

CD70: An emerging target in cancer immunotherapy. Pharmacol Ther (2015) 0.81

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. J Natl Cancer Inst (2015) 0.80

Effects of loss of p53 and p16 function on life span and survival of human urothelial cells. Int J Cancer (2005) 0.80

Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncol Rep (2006) 0.80

CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer (2007) 0.80

Harnessing the Therapeutic Potential of Th17 Cells. Mediators Inflamm (2015) 0.80

Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology (2014) 0.79

Optimal delivery of colorectal cancer follow-up care: improving patient outcomes. Patient Relat Outcome Meas (2015) 0.79

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology (2014) 0.79

Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget (2015) 0.78

Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis. Int J Clin Exp Med (2015) 0.76

Determination of the activity of CD134 (OX-40) and CD137 (4-1BB) adhesive molecules by means of flow cytometry in patients with colorectal cancer metastases to the liver. Pol Przegl Chir (2011) 0.76

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget (2015) 0.76

The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population. Int J Immunogenet (2015) 0.76

Association between cytotoxic T-lymphocyte antigen-4 +49A/G polymorphism and colorectal cancer risk: a meta-analysis. Int J Clin Exp Med (2015) 0.76

Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients. Pol Przegl Chir (2011) 0.75